Latest News

Eleonora Lad, MD, PhD, Dimitra Skondra, MD, PhD, and John Kitchens, MD, point to structure and function, diet and the gut, and the future of reimbursement.

Spectacle lenses with highly aspherical lenslets are safe and effective for reducing myopia progression in US children.

CHMP backs Accord Healthcare’s Lucentis biosimilar Fovlussea for nAMD, DMO, RVO and CNV ahead of an EC decision.

Enrollment in the licaminlimab trial closed above target, with two-thirds of 176 patients carrying a TNFR1 variant associated with stronger treatment response. Topline data are expected around year-end 2026.

Prevent Blindness marks IED Week, October 19 to 25, as new therapies and pivotal trials reshape care for uveitis and thyroid eye disease.

Second phase 3 trial of Duravyu misses wet AMD noninferiority end point; EyePoint cuts 53% of staff to focus on DME.

The nonprescription 0.125% apraclonidine drop is approved for adults and children 12 years and older, and Alcon says each dose whitens the eye for up to 12 hours.

Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier timepoints.

Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.

Two phase 1 OSPREY cohorts of intravitreal STK-002 for ADOA are dosed; first safety and efficacy data are expected by mid-2027.

A higher risk of central serous chorioretinopathy and serous pigment epithelial detachment are associated with varicose veins.

Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for optometrists managing near vision loss.

Enspryng is the first subcutaneous, at-home treatment option for TED and the first interleukin (IL)-6 receptor inhibitor approved in the indication.